Powerpoint presentation by dr sathiha
-
Upload
zawhtet1984 -
Category
Education
-
view
1.443 -
download
2
description
Transcript of Powerpoint presentation by dr sathiha
![Page 1: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/1.jpg)
Standard BEACOPP Chemotherapy Standard BEACOPP Chemotherapy Compared with COPP-ABVD for Compared with COPP-ABVD for Advanced Hodgkin's DiseaseAdvanced Hodgkin's Disease
Moscow State UniversityMoscow State UniversityFaculty of Fundamental MedicineFaculty of Fundamental MedicineN.N.Blokhin Cancer Research Center
Presented By : Dr .Sa Thi Ha (M.B;B.S)Supervisor : Prof Dr.B.I.Polyakov Dr.D.A.Bykov17th may 2010
![Page 2: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/2.jpg)
Introduction Hodgkin lymphoma is characterized by the
presence of a special type of lymphatic cell called a Reed-Sternberg (RS) cell.
look like "owl's eyes.
more common in young adults and elderly patients.
![Page 3: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/3.jpg)
Reed-Sternberg cell
![Page 4: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/4.jpg)
population8510 new cases (2009)
4640males and 3870 females
1290 died (800 males and 490 females in 2009)
![Page 5: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/5.jpg)
Risk factors Age Family history SexPast Epstein-Barr infectionCompromised immune systemGeography Socioeconomic status
![Page 6: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/6.jpg)
Signs and symptom (+) of B symptomsAlcohol-induced pain in the enlarged nodes Enlarged lymph nodes (firm and rubbery)Hepatosplenomegaly Back pain Petechiae
![Page 7: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/7.jpg)
Diagnosis History taking and physical examination Investigation Blood cell count (ESR) MRI PET scan Biopsy BM examination
![Page 8: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/8.jpg)
Treatment Chemotherapy RadiotherapyStem cell transplantSurgery Target therapy Immunotherapy
![Page 9: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/9.jpg)
Chemotherapy ABVD(Adriamycin, bleomycin, vinblastine
and dacarbazine).BEACOPP(bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
Stanford V( doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin and prednisone).
COPP/ABVD(cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine and dacarbazine)
MOPP( mechlorethamine, vincristine, procarbazine and prednisone)
![Page 10: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/10.jpg)
The studied prognostic factors Age >45 year versus <45 Gender Type of disease: early disease versus advanced
disease Presence of B symptoms ESR > 50 or > 30 plus B symptoms versus neither LDH > 500 IU/L versus < 500 IU /L Extranodal involvement Mediastinal involvement Pathological subtypes Type of chemotherapy
![Page 11: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/11.jpg)
Aim of study
To identify various methods of combination therapy in advanced Hodgkin’s lymphoma and which is best and less toxicity.
![Page 12: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/12.jpg)
Research objective To evaluate rate of freedom from treatment failure
at 5 years in treatment of standard BEACOPP and ABVD-COPP
To identify outcome and 5 years survival rates in standard BEACOPP and ABVD-COPP
To determine the toxicity of long term chemotherapy
![Page 13: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/13.jpg)
Methods and materials Study method … retrospective method No of patients …49 patients(25-BEACOPP
and 24-COPP-ABVD)Duration of study …January 2005 to
December 2009.Staging …Ann Arbor clinical stage IIB or IIIA
and above stage with a large mediastinal mass Work-up - chest x-ray, CT of the abdomen and
pelvis, and complete blood count and ESR with metabolic profile
![Page 14: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/14.jpg)
55 patients recruited
28 Assigned to BEACOPP27 Assigned to COPP-ABVD
2 Excluded 2 did not have Hodgkin’s disease
2 Excluded 2 did not have Hodgkin’s disease
26 Eligible 1 lost to follow up 25 Elgible 1 lost to follow up
25 Included in the analysis 23 received full course 2 received partial course
24 Included in the analysis 20 received full course 4 received partial course
Numbers of patients included in this analysis
![Page 15: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/15.jpg)
Characteristics of patients
![Page 16: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/16.jpg)
Chacteristics of patients by stage
![Page 17: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/17.jpg)
Acute Adverse Effects of Chemotherapy
![Page 18: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/18.jpg)
Kaplan–Meier Analysis of the Probability of Freedom from Treatment Failure (Panel A) and Overall Survival (Panel B)
![Page 19: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/19.jpg)
Rate of the early progression and Five year Kaplain-Meier estimates of
the rate of free from treatment failure according to the International
Prognostic Index.
International Prognostic IndexCOPP-ABVD
(%)
Standard
BEACOPP(%)Early progression Good (0-1)Fair (2-3)Poor (4-7)Freedom from treatment failure at 5 yearsGood (0-1)Fair (2-3)Poor (4-7)Overall survival at 5 years Good (0-1)Fair (2-3)Poor (4-7)
101118
796759
928467
699
817274
938681
![Page 20: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/20.jpg)
Outcome of Treatment and Five-Year Survival Rates.
Variable
COPP-ABVD(N=24)
Standard BEACOPP(N=25) percent
Complete remission 85(80-89) 88(85-91)
Early progression 10(7-15) 8(5-10)
Freedom from treatment failure at 5 yr
69(63-75) 76(72-80)
Overall survival at 5 yr 83(78-87) 88(85-91)
![Page 21: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/21.jpg)
Conclusion The rate of freedom from treatment failure at five years
was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group.
The five-year rates of overall survival were 83percent COPP-ABVD, the comparison with 88 percent of BEACOPP group. Standard BEACOPP results in better tumor control and overall survival than did COPP-ABVD.
The incidence of acute toxicity increases with BEACOPP; grade 4 leukopenia occurred in one or more cycles.
![Page 22: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/22.jpg)
![Page 23: Powerpoint presentation by dr sathiha](https://reader033.fdocuments.us/reader033/viewer/2022061117/54661938b4af9f493f8b5165/html5/thumbnails/23.jpg)
Thank you for attention